Considerations in the Management of Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy

Abstract excerpt

The phenomenal success of therapy with tyrosine kinase inhibitors (TKIs) in Philadelphia chromosome (Ph) –positive chronic myeloid leukemia (CML) has drastically changed the prognosis of this disease. With imatinib mesylate, the estimated 7- to 10-year survival is 80% to 85%, 90% to 93% if only CML-related deaths are considered.1–5 Nilotinib and dasatinib are more potent second generation TKIs with activity in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chronic Lymphocytic Leukemia Research
• Share to Chronic Myeloid Leukemia Treatments
• Share to Eosinophilic Disorders and Syndromes